[1] |
1. Younes M, Schwartz MR, Ertan A, et al. Fas ligand expression in esophageal carcinomas and their lymph node metastases[J]. Cancer, 2000, 88(3):524-528. 2. Song E, Chen J, Ouyang N, et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer [J], Br J Cancer, 2001, 85(7):1047-1054. 3. Mitsaides N, Yu WH, Poulaki V, et al. Matrix metalloproteinase— 7 —mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity [J], Cancer Res, 2001, 61(2): 577-581. 4. Das H, Imoto S, Murayama T, et al. Levels of soluble FasL and FasL gene expression during the development of graft—versus — host disease in DLT—treated patients[J]. Br J Haematol, 1999, 104.(4):795-800. 5. Tsutsumi S, Kuwano H, Shimura T, et al. Circulating soluble Fas ligand in patients with gastric carcinoma[J]. Cancer, 2000, 89(12): 2560-2564. 6. Mizutani Y, Hongo F, Sato N, et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma[J]. Cancer, 2001, 92 (2):287-293. 7. Hsieh MH, Korngold R. Differential use of FasL and perforin— mediated cytolytic mechanisms by T —cell subsets involved in graft—versus—myeloid leukemia responses [J]. Blood, 2000, 96(3): 1047-1055. 8. Zeytum A, Nagarkatti M, Nagarkatti PS. Growth of FasL—bearing tumor cells in syngeneic murine host induces apoptosis and toxici -ty in Fas+organs[J]. Blood, 2000, 95(6):2111-2117. 9. Schneider P, Holler N, Bodmer JJL, et al. Conversion of mem-brance—bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity[f].JExpMed, 1998, 187(8):1205-1213. 10. LiuJH, Wei S, Lamy T, et al. Chronic neutropenia mediated by Fas ligand[J]. Blood, 2000, 95(10):3219-3222. 11. 刘陶文,黎金庆,廖东,等.急性白血病患者血清中可溶性Fas配基含量的变化田.实用癌症杂志,2002,17(1):48-50. 12. Martinez—Lorenzo MJ, Anel A, Gamen S, et al. Activated human T cells release bioactive Fas ligand and Apo 2 ligand in microvesi-cles[J].JImmunol, 1998, 163(3):1274-1281.
|